Prelude Therapeutics Incorporated (PRLD) EPS by Year
PRLD
Prelude Therapeutics Incorporated lost $1.29 per diluted share in fiscal year 2025. This represents an increase of 23.2% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $0.73 per diluted share. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Prelude Therapeutics Incorporated has filed alongside them.
FY2025 annual
EPS (Diluted)-$1.29
YoY+23.2%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
PRLD EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Prelude Therapeutics Incorporated's diluted earnings per share in fiscal year 2025?
Prelude Therapeutics Incorporated lost $1.29 per diluted share in fiscal year 2025.
How fast is Prelude Therapeutics Incorporated's diluted earnings per share growing?
Prelude Therapeutics Incorporated (PRLD) diluted earnings per share rose by 23.2% year over year, from -$1.68 to -$1.29 in fiscal year 2025.
What is Prelude Therapeutics Incorporated's diluted earnings per share over the last twelve months?
Prelude Therapeutics Incorporated (PRLD) reported a loss of $0.73 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Prelude Therapeutics Incorporated's diluted earnings per share in the most recent quarter?
Prelude Therapeutics Incorporated (PRLD) reported -$0.14 in diluted earnings per share in Q2 2026. This represents an increase of 65.9% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Prelude Therapeutics Incorporated (PRLD) reported on that line in every period on record.
